About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 1463 record(s)
Req # A-2022-000840
Adverse Drug Reactions (ADRs) for Rexulti. Report numbers: E2B_05427218, E2B_05428797. ADRs for Sucroferric Oxyhydroxide. Report numbers: E2B_05461870, E2B_05421443. ADRs for PATIROMER. Report numbers: E2B_05406096, E2B_05321703, E2B_05322447, E2B_05339226, E2B_05363908.Organization: Health Canada
December 2022
Req # A-2022-000841
Adverse Drug Reactions (ADRs) for ARIPIPRAZOLE. Report numbers: 000991892, 000992206. ADRs for ABILIFY MAINTENA. Report numbers: E2B_05310329, E2B_05403666, E2B_05419315. ADRs for ABILIFY. Report numbers: E2B_05395846, E2B_05397654, E2B_05426970, E2B_05427216.Organization: Health Canada
December 2022
Req # A-2022-000842
Adverse Drug Reactions (ADRs) for PATIROMER. Report numbers: E2B_05512087, E2B_05527201, E2B_05589015. ADR for Inqovi. Report number: E2B_05370335. ADRs for Abilify. Report numbers: 001003144, 001003902, E2B_05566840. ADRs for Sucroferric Oxyhydroxide. Report numbers: E2B_05545482, E2B_05555520. ADR for Rexulti. Report number: E2B_05602670.Organization: Health Canada
December 2022
Req # A-2022-000856
Adverse Drug Reactions (ADRs). Report numbers: E2B_05041695, E2B_05041688, E2B_05041681, E2B_05041676, E2B_05040674, E2B_05041660, E2B_05040698, E2B_05041583, E2B_05040705, E2B_05041582.Organization: Health Canada
December 2022
Req # A-2022-000859
Adverse Drug Reactions (ADRs). Report numbers: E2B_05040741, E2B_05040742, E2B_05040744, E2B_05040745, E2B_05040746, E2B_05041530, E2B_05041529, E2B_05040762, E2B_05041524, E2B_05040965.Organization: Health Canada
December 2022
Req # A-2022-000861
Adverse Drug Reactions (ADRs). Report numbers: E2B_05041340, E2B_05040733, E2B_05041334, E2B_05040977, E2B_05040931, E2B_05040967, E2B_05040971, E2B_05040960, E2B_05040919, E2B_05040865.Organization: Health Canada
December 2022
Req # A-2022-000862
Adverse Drug Reactions (ADRs). Report numbers: E2B_05040858, E2B_05040787, E2B_05040740, E2B_05040648, E2B_05045934, E2B_05046035, E2B_05046446, E2B_05046732, E2B_05046437, E2B_05045986.Organization: Health Canada
December 2022
Req # A-2022-000864
Adverse Drug Reactions (ADRs). Report numbers: E2B_05046762, E2B_05046461, E2B_05047119, E2B_05047191, E2B_05047342, E2B_05046665, E2B_05046703, E2B_05046965.Organization: Health Canada
December 2022
Req # A-2022-000868
Adverse Drug Reactions (ADRs). Report numbers: E2B_03051153, E2B_05593757, 000997301, 001003640, 000999796, E2B_05550964, E2B_05561001, E2B_05593615.Organization: Health Canada
December 2022
Req # A-2022-000891
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-113866-373.Organization: Health Canada
December 2022